ACTT-1
Remdesivir for the Treatment of COVID-19
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 1,062 hospitalised COVID-19 patients, remdesivir shortened time to recovery compared with placebo.
N
1.062
Design
Double-blind RCT, NIAID
Endpunkt
Time to recovery
Relevanz
3
Ergebnis10 vs 15 days; 28-d mortality 11.4% vs 15.2% (HR 0.73; NS).
Beigel JH, et al. N Engl J Med. 2020;383(19):1813-1826. 10.1056/NEJMoa2007764
Diskussion & Kritik
Faster recovery without convincing mortality signal; later WHO SOLIDARITY pooling neutral.